https://pepsreview.com/articles/saxenda-users-join-naion-litigation-vision-loss-claims-expand-liraglutide PepsReview en 2026-09-14 Saxenda lawsuit, liraglutide NAION, GLP-1 litigation, vision loss, Novo Nordisk, NAION claims, incretin safety, drug safety news https://pepsreview.com/articles/australian-patient-torn-oesophagus-unapproved-peptide PepsReview en 2026-09-14 peptide safety Australia, unapproved peptide, torn oesophagus, TGA warning, gray market peptides, peptide injury, research peptide testing https://pepsreview.com/articles/zepbound-lawsuits-2026-who-qualifies-file-claim PepsReview en 2026-09-14 Zepbound lawsuit, GLP-1 litigation, tirzepatide lawsuit, Eli Lilly, gastroparesis lawsuit, GLP-1 MDL, who qualifies, drug injury claim https://pepsreview.com/articles/empower-pharmacy-lawsuit-widens-2026-claims-compounded-glp-1s PepsReview en 2026-09-13 Empower Pharmacy lawsuit, compounded semaglutide, compounded tirzepatide, 503B outsourcing facility, GLP-1 litigation, FDA warning letter, peptide testing https://pepsreview.com/articles/fda-coordinated-enforcement-sweep-targets-peptide-sellers PepsReview en 2026-09-13 FDA enforcement, peptide sellers, FDA sweep, unapproved peptides, peptide regulation, GLP-1 enforcement, peptide import screening https://pepsreview.com/articles/verification-tools-proliferate-as-peptide-buyers-demand-proof PepsReview en 2026-09-13 peptide claims verification, evidence checker, peptide purity testing, COA verification, research peptide market, peptide quality control, third party testing https://pepsreview.com/articles/market-intelligence-index-tracks-100-peptide-vendors-112000-public-coa-records PepsReview en 2026-09-13 peptide market intelligence, peptide vendor comparison, COA records, peptide prices, research peptide market, peptide testing, vendor transparency https://pepsreview.com/articles/oral-glp-1-prescriptions-keep-climbing-tablets-find-their-place PepsReview en 2026-09-12 oral GLP-1, Wegovy pill, orforglipron, oral semaglutide, GLP-1 prescriptions, weight loss tablet, peptide testing, counterfeit peptides https://pepsreview.com/articles/glp-1-weight-loss-market-under-fire-big-promises-regulatory-reality PepsReview en 2026-09-12 GLP-1 market, weight loss marketing, compounded semaglutide, compounded tirzepatide, FDA enforcement, peptide purity, telehealth weight loss https://pepsreview.com/articles/fda-approves-eli-lilly-oral-glp-1-weight-loss-pill PepsReview en 2026-09-12 orforglipron, Eli Lilly, FDA approval, oral GLP-1, weight loss pill, obesity medication, GLP-1 news https://pepsreview.com/articles/semaglutide-shortage-ends-window-closes-for-compounded-copies PepsReview en 2026-09-12 semaglutide shortage, compounded semaglutide, FDA shortage list, compounding pharmacies, 503B, GLP-1 supply, enforcement https://pepsreview.com/articles/retatrutide-remains-investigational-2026-phase-3-triumph-readouts PepsReview en 2026-09-12 retatrutide, retatrutide FDA status, TRIUMPH phase 3, triple agonist peptide, Eli Lilly obesity drug, gray market peptides, investigational peptide, GLP-1 research https://pepsreview.com/articles/independent-peptide-testing-capacity-expands-purity-concerns PepsReview en 2026-09-12 peptide testing, HPLC purity testing, LC-MS analysis, certificate of analysis, independent lab testing, research peptide purity, third party verification